Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech announced the launch of diabetic retinopathy screenings in partnership with Grupo Dökka's pharmacy chains Fischel and La Bomba in Central America. The initiative utilizes Ainnova's AI platform, Vision AI, to perform quick, non-invasive retinal scans for early detection of diabetic retinopathy. The program offers free screenings to diabetic customers, aiming to identify retinal changes before they affect vision. CEO Vinicio Vargas highlighted plans to expand similar initiatives to Mexico, focusing on integrating pharmaceutical, retail, and ophthalmology services. Grupo Dökka, operating in Costa Rica, Nicaragua, and Panama, plans to expand its healthcare platforms across Central America.

Positive

• Partnership with established pharmacy chains (Fischel and La Bomba) provides immediate market access
• Expansion plans into Mexico indicate growth potential
• Free screening program could drive customer adoption and market penetration
• Integration of AI technology with healthcare providers creates comprehensive service offering

Negative

• Early stage of implementation with unproven market success
• Limited initial geographic reach in Central American markets
• No revenue metrics or financial projections provided

LAS VEGAS, June 17, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that screenings for diabetic retinopathy begin this week in collaboration with Grupo Dökka and its leading pharmacy subsidiaries, Fischel Pharmacies and La Bomba Pharmacies located in Central America.

Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, to help identify changes in the retina using a quick and non-invasive scan of the patient's retina.

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp., a joint venture company created by both Avant and Ainnova, said of the benefits for the collaboration, "As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment—connecting every step of the journey. We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive: the well-being of the diabetic patient. Projects like this allow us to validate the model across diverse populations and sectors as part of our strategy to reach the market in a smarter, more efficient way—where the biggest winners are the patients."

Diabetic retinopathy is one of the main causes of vision loss in people with diabetes. Although, in its early stages, it may not present symptoms, it can be detected with a simple and quick screening. The screenings are important for:

Prevention: Screenings will detect changes in the retina before they affect vision.

Speed: Each screening takes only a few minutes.

Peace of Mind: Patients will receive the results of the screening in a secure and timely manner.

Grupo Dökka, which operates in Costa Rica, Nicaragua, and Panama with expansion expected into other Central American countries, has created numerous innovative platforms, including storage and distribution, pharmacies, and marketing and sales, that provide access to comprehensive health and well-being solutions for all people.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc. 

Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies, Inc. info@avanttechnologies.com

Video: https://mma.prnewswire.com/media/2712681/Avant_Technologies.mp4
Logo: https://mma.prnewswire.com/media/2370694/5373988/Avant_Technologies.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-jv-partner-ainnova-begins-diabetic-retinopathy-screenings-with-leading-pharmacies-302483739.html

SOURCE Avant Technologies Inc.

FAQ

What is Avant Technologies' (AVAI) role in diabetic retinopathy screening?

Avant Technologies, through its JV partner Ainnova, is providing AI-powered retinal scanning technology called Vision AI for diabetic retinopathy screening at Fischel and La Bomba pharmacies in Central America.

Which pharmacies are participating in AVAI's diabetic retinopathy screening program?

Fischel Pharmacies and La Bomba Pharmacies, both subsidiaries of Grupo Dökka operating in Costa Rica, Nicaragua, and Panama, are participating in the screening program.

How does Ainnova's Vision AI screening technology work?

Vision AI performs quick, non-invasive scans of patients' retinas to detect early changes associated with diabetic retinopathy before they affect vision.

What are Avant Technologies' expansion plans for the screening program?

The company plans to expand similar screening initiatives into Mexico, focusing on integrating pharmaceutical, retail, and ophthalmology services into a unified experience.

Is the diabetic retinopathy screening free for patients?

Yes, diabetic customers at participating Fischel and La Bomba pharmacies are being offered free screenings as part of the program.